Blogs Archives

January 28, 2025

I Missed It by That Much: CR but No uMRD by 1 per Million

Testing for measurable residual disease (MRD) through next-generation sequencing (NGS) with clonoSEQ revealed zero to one cell per million in the blood.

January 6, 2025

CLL is Still in Retreat on My Epcoritamab Trial

I started epcoritamab, a bispecific antibody, in August 2023, and now, entering 2025, I continue to do well in complete remission with low levels of MRD.

August 26, 2024

One Year Into My CLL Epcoritamab Trial, and All Is Well

One year after Dr. Brian Koffman enrolled as the first chronic lymphocytic leukemia (CLL) patient in the epcoritamab clinical trial, all is well.

May 31, 2024

My CLL is Not Gone; Close, but Not Gone

My CLL wasn’t detectable in my bloodstream after about six months in my epcoritamab trial, it almost certainly was still hiding below the level of detection.

May 9, 2024

How MRD Testing Helped Guide My CLL Treatment Decisions

It’s been a month since my last post on progress in my trial of epcoritamab, a bispecific T cell engager (BiTE) for my chronic lymphocytic leukemia.

February 22, 2024

More Good News in my Epcoritamab CLL Trial and an FDA Panel

It’s been a month since my last post on progress in my trial of epcoritamab, a bispecific T cell engager (BiTE) for my chronic lymphocytic leukemia.

January 17, 2024

More Good News From My CLL Trial: uMRD in the Blood with Epcoritamab

I found out last week that I am not only in a complete remission, but also there was no measurable CLL in my peripheral blood done by flow cytometry, down to 1 in 10,000 cells

January 3, 2024

New Year’s Update and Outlook for My Epcoritamab Trial

The beginning of a new calendar year is not a good reason to make radical changes, but it may mark a timely moment to reflect on what’s gone well and what could be better going forward.

December 15, 2023

Good News From My Clinical Trial for CLL as I Head to ASH 2023

With my CLL well controlled, my IVIG aboard, and my epcoritamab injections now every two weeks, the timing is perfect. I am in good shape heading to ASH.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Blogs

I Missed It by That Much: CR but No uMRD by 1 per Million

CLL is Still in Retreat on My Epcoritamab Trial

One Year Into My CLL Epcoritamab Trial, and All Is Well

My CLL is Not Gone; Close, but Not Gone

How MRD Testing Helped Guide My CLL Treatment Decisions

More Good News in my Epcoritamab CLL Trial and an FDA Panel

More Good News From My CLL Trial: uMRD in the Blood with Epcoritamab

New Year’s Update and Outlook for My Epcoritamab Trial

Good News From My Clinical Trial for CLL as I Head to ASH 2023

CLL SOCIETY FAST FIND

QUICK LINKS

ABOUT CLL SOCIETY

CONTACT